Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734(TM)) in Participants With Severe Coronavirus Disease (COVID-19)

Study Overview

The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.

Study Description

GS-US-540-5773: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants with Severe COVID-19

  • ClinicalTrials.gov Identifier: NCT04292899
  • Protocol Number: 2020C000247
  • Principal Investigator: Kathryn Stephenson

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000